How to achieve renal protection in the light of ontarget?

Journal of Hypertension

Volumn 27, Issue SUPPL. 2, 2009, Pages

  Chatzikyrkou, Christos ^a   Menne, Jan ^a   Haller, Hermann ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Proteinuria; Ramipril; Renal function; Telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RAMIPRIL; TELMISARTAN;

ALBUMINURIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT RESPONSE; ARTICLE; DRUG COMBINATION; KIDNEY; PATHOPHYSIOLOGY;

CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY; RENIN-ANGIOTENSIN SYSTEM;

EID: 69449098744     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000354514.59827.04     Document Type: Review

References (16)

1. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369:1208-1219.
2. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the rennin-angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30-48.
3. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-771. (Pubitemid 37093916)
4. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
5. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al., ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547-553.
6. Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167:1930-1936.
7. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48:8-20.
8. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117-124. (Pubitemid 36092015)
9. Kunz R, Wolbers M, Glass T, Mann JF. The COOPERATE trial: a letter of concern. Lancet 2008; 371:1575-1576.
10. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al., The Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16:2170-2179.
11. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al., REIN-2 Study Group. Blood-pressure control for renoprotection in patients with nondiabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365:939-946.
12. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45:880-886.
13. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
14. Velez JC. The importance of the intrarenal renin-angiotensin system. Nat Clin Pract Nephrol 2009; 5:89-100.
15. Arici M, Erdem Y. Dual blockade of the renin-angiotensin system for cardiorenal protection: an update. Am J Kidney Dis 2009; 53:332-345.
16. O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, et al., VA NEPHRON-D Investigators. Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009; 4:361-368.